Articles
We’re celebrating a significant milestone at Optimal! We're thrilled to share that our team has achieved a 100% retention rate for participants in an RSV clinical trial for older adults. This not only underscores the exceptional experience patients receive at Optimal, but also highlights our industry-leading participant retention rates.
Why is retention so critical? On average, it costs over USD $6,500 to recruit a trial participant. The cost triples to replace them if one drops out of the study.
More than just numbers, this study is crucial. RSV isn't just contagious; it's a potentially serious respiratory threat, leading to complications like pneumonia, bronchitis, and even cardiac issues. Particularly in New Zealand, respiratory tract infections rank high among reasons for hospitalisations and stand as the 9th leading cause of death for those over 65. Remarkably, individuals over 65 tend to contract at least one respiratory tract infection yearly. And currently, there's no vaccine.
Thank you to our study sponsor and CRO for making us a part of this transformative clinical study. Together, we're paving the way for potential breakthroughs in medicine.